Search Results
Your search for ,WhO matches 21068 pages
Showing 17601 - 17650ASCO Guideline Update Extends Sentinel Node Biopsy Indications in Breast Cancer
The American Society of Clinical Oncology (ASCO) published its first guideline for sentinel lymph node biopsy in 2005.1 Since that time, many new randomized and cohort studies have been published investigating the indications and outcomes of the procedure. The updated 2014 guideline, recently...
ASCO Clinical Practice Guideline Update: Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer
ASCO recently convened an update committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy to develop evidence-based recommendations that update the ASCO 2005 clinical practice guideline on use of sentinel node biopsy in...
Unprecedented Release of Medicare Data Raises Concerns About Lack of Context: Statements From COA and ASTRO
In April, as part of the Obama administration’s work to make the U.S. health-care system more transparent, affordable, and accountable, the Centers for Medicare & Medicaid Services (CMS) released a vast amount of privacy-protected data on services and procedures provided to Medicare...
Patients Benefit From Faster FDA Drug Approval Process
In an increasing spirit of cooperation, U.S. Food and Drug Administration (FDA) and several pharmaceutical companies are bringing to fruition the newest in a series of ways to expedite drug development and review. Breakthrough therapy is the designation instituted in 2012 by the FDA Safety and...
Looking Ahead in Treating Chronic Lymphocytic Leukemia
It’s the dawn of a new era in the treatment of chronic lymphocytic leukemia (CLL), largely due to the development of agents targeting the BCR signaling pathway, according to John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, Columbus. At the 19th Annual Conference of the...
NCCN Roundtable: When a Parent Has Cancer
Attendees at this year’s annual conference of the National Comprehensive Cancer Network (NCCN) not only got up to date on the Guidelines but left with a better understanding of how children deal with a parent’s cancer, and how oncology providers can best help. Panelists for the NCCN roundtable...
NCCN Scientific Posters Include New Findings in Bladder Cancer, Survivorship Care, and Antiemetic Therapy
The 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), recently held in Hollywood, Florida, featured a number of scientific posters by member organizations and meeting sponsors. The ASCO Post captured some of the most interesting findings for our readers, including these...
Study Calls for Revisiting Guidelines for Screening Childhood Cancer Survivors at Risk of Congestive Heart Failure
One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure found improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit. The...
Surveillance After Colon Cancer Surgery: Too Much of a Good Thing?
Finding salvageable colon cancer recurrence is akin to finding a needle in a haystack, rendering routine patient surveillance of little value. But finding that needle offers an opportunity for treating recurrent disease early, which makes surveillance worthwhile. These were the opposing views...
Glioblastoma: Can We Make This Intractable Disease Tractable?
In the clinical array of brain tumors, glioblastoma is the most difficult to treat, and despite decades of research and the advent of new therapies, patients with glioblastoma continue to have a very poor prognosis. Leading brain tumor experts at the recent 25th Annual Cancer Progress Conference in ...
Mercaptopurine Oral Suspension for Acute Lymphoblastic Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 28, 2014, an oral suspension of mercaptopurine (Purixan) ...
Axillary Radiotherapy Associated With Fewer Side Effects Than Lymph Node Dissection in AMAROS Analysis
Radiation therapy is associated with significantly fewer postoperative complications than axillary lymph node dissection, according to a detailed analysis of morbidity from the AMAROS (After Mapping of the Axilla: Radiotherapy or Surgery?) trial presented at a press briefing prior to the American...
Cryoablation of Breast Tumors Shows Promise in Patients With Early-Stage Disease
Cryoablation of breast tumors, which destroys lesions by exposing them to extremely low temperatures, shows promise as an alternative to surgery in carefully selected women with early-stage disease, according to a study presented at the American Society of Breast Surgeons Annual Meeting in Las...
Expert Point of View: Clifford A. Hudis, MD, FACP
“To our surprise, obesity had a negative prognostic effect on premenopausal patients with breast cancer but not on those who were postmenopausal. We need to consider these findings in the context of results from other data sources that suggest that obesity remains a negative prognostic feature in...
Obesity Increases Breast Cancer Mortality in Premenopausal Women With Estrogen Receptor–Positive Disease
According to results of a large study of women with early breast cancer, the presence of obesity increased the risk of breast cancer–related mortality by 34% in premenopausal women with estrogen receptor–positive breast cancer. Obesity had little effect on breast cancer–related mortality in...
Expert Point of View: Peter P. Yu, MD
Commenting on the study by Jänne et al, ASCO President Peter P. Yu, MD, said that the issue of drug resistance is important to understand for all cancers, but it is difficult to overcome resistance. “This clinical trial has important implications not only for NSCLC patients but for all patients...
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Preliminary evidence suggests that AZD9291, a novel mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, may become a treatment option for patients with advanced, EGFR-mutant, non–small cell lung cancer (NSCLC) that has progressed on standard EGFR inhibitors....
'Small Practices Like Mine'
Recently, I participated in ASCO’s Congressional news briefing in Washington, DC, following the release of its report, The State of Cancer Care in America: 2014. During my presentation I talked about the workforce shortage of approximately 1,500 medical oncologists that is predicted by 2025. A...
Expert Point of View: Michael J. Morris, MD
Formal discussant of the E3805 study, Michael J. Morris, MD, Associate Member at Memorial Sloan Kettering Cancer Center in New York, said that these results confirm the role of upfront chemotherapy along with androgen-deprivation therapy in men with newly diagnosed metastatic hormone-sensitive...
‘Unprecedented’ Survival Benefit in Prostate Cancer With Addition of Docetaxel to Hormone Therapy
Adding docetaxel to standard androgen ablation therapy (ie, testosterone suppression) extended survival by more than 1 year in men with newly diagnosed metastatic hormone-sensitive prostate cancer in the phase III E3805 trial, funded by the National Institutes of Health. As reported at the ASCO...
Sharing 50 Years of Christmas: A Quality Metric?
A very pleasant 68-year-old woman was referred to my clinic with biopsy-proven liver metastasis from primary colon cancer. She was initially diagnosed with colon cancer, which was resected, and she then received chemotherapy. A suspicious liver lesion was biopsied in the adjuvant setting, which...
Leading Cancer Researcher and Public Health-Care Expert, Eddie Reed, MD, Dies
In a 2010 interview, Eddie Reed, MD, a pioneer in the molecular pharmacology of DNA-damaging anticancer agents and the clinical development of paclitaxel for ovarian cancer, was asked what lay ahead. Before answering, Dr. Reed first acknowledged the esteemed mentors who gave him their most precious ...
Colorectal Cancer Screening Recommended Past Age 75 for Previously Unscreened Patients
Colorectal cancer screening is cost-effective and “should be considered well beyond age 75 years” for individuals not previously screened, according to a computer simulation study published in the Annals of Internal Medicine. The researchers noted that while the U.S. Preventive Services Task Force...
Expect Questions From Patients
With the extensive media coverage of a study indicating that injections with the luteinizing hormone–releasing hormone (LHRH) agonist goserelin (Zoladex) may offer a new option for preserving fertility among women treated for breast cancer, physicians can expect questions from interested patients....
New Option for Preserving Fertility in Women Being Treated With Chemotherapy for Early-Stage Breast Cancer
One of the most reported studies emanating from the 2014 ASCO Annual Meeting involves the use of the luteinizing hormone–releasing hormone (LHRH) agonist goserelin (Zoladex) to reduce the risk of ovarian failure among women being treated with chemotherapy for early-stage breast cancer, and to...
Physician Attitudes About Multiplex Tumor Genomic Testing: Variation in Projected Use and Confidence
It is a widely expressed belief that predictive multiplex somatic genomic testing represents the ability to transform cancer care by identifying targetable alterations in multiple cancer genes. Do oncologists share this belief? How do they intend to use such tests in practice? In a study reported...
Cancer Care Under the Affordable Care Act
The problematic rollout of the Affordable Care Act’s website, HealthCare.gov, made good political theater, but while much of the heated discussion centered on the plan’s need to enroll “young invincibles,” America’s cancer care system and the older patients it serves were also affected by parts of...
David Craig, PharmD, Named to FDA Advisory Committee
Moffitt Cancer Center recently announced that Clinical Pharmacist David Craig, PharmD, has been appointed to the U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee. Dr. Craig specializes in pain medicine and palliative care. The Anesthetic and Analgesic...
Marie-Josée and Henry R. Kravis Foundation Provides $100 Million Gift to Support Precision Oncology Work at Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center has launched an initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice. The Marie-Josée and Henry R. Kravis...
Colon Cancer Prevention: It’s All About Mindset and Minute Details
I would like to congratulate Corley and his colleagues for their seminal work on the association between adenoma detection rate and risk of colorectal cancer, advanced colorectal cancer, and colorectal cancer mortality. The impact of their findings—reported in The New England Journal of Medicine1...
Colonoscopy Adenoma Detection Rate Inversely Proportional to Risk of Interval Colorectal Cancer and Colorectal Cancer Mortality
In a study of health-care organization data reported in The New England Journal of Medicine, Douglas A. Corley, MD, PhD, of Kaiser Permanente, and colleagues assessed the relationship between proportion of colonoscopies performed by a gastroenterologist that detect an adenoma and risk of subsequent ...
Issues in the Management of the Axilla in Patients With Breast Cancer
For the past 40 years the story of breast cancer surgery in general, and for the past 20 years the management of the axilla in particular, has been one of increasing conservatism. To give our readers insight into the current and future direction of axillary management, The ASCO Post spoke with...
A New Era in the Management of Advanced HER2-Positive Breast Cancer
Approximately 20% of all breast cancers are human epidermal growth factor receptor 2 (HER2)-positive. Prior to the era of HER2-targeted therapy, HER2-positive breast cancer was characterized by a poor prognosis.1,2 The development of the first HER2-targeted therapy, trastuzumab (Herceptin), led to...
ASCO Clinical Practice Guideline: Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
Approximately 15% of patients with breast cancer have tumors that overexpress the HER2 protein and these patients can benefit from HER2-targeted therapies. The American Society of Clinical Oncology recently released a clinical practice guideline on systemic therapy for patients with advanced...
The 2014 Conquer Cancer Foundation Grants and Awards
The Conquer Cancer Foundation of ASCO presented more than $5 million in grants and awards to more than 250 promising oncology researchers at the 2014 ASCO Annual Meeting, held May 30 to June 3 in Chicago, Illinois. The Conquer Cancer Foundation and ASCO congratulate the 2014 grant and award...
ASCO’s Patient Information Website, Cancer.Net, Undergoes Redesign
ASCO is committed to providing people with cancer and their caregivers with top quality educational information and resources to help them manage their cancer care, treatment, and survivorship. This ongoing commitment is best reflected in its patient-facing educational website, Cancer.Net...
Conquering Cancer With 2013 Career Development Award Recipient Rebecca A. Gardner, MD
Rebecca A. Gardner, MD is an Assistant Professor at the University of Washington and Attending Physician at Seattle Children’s Hospital. She received a 2013 Conquer Cancer Foundation of ASCO Career Development Award (CDA) for her project “Autologous T cells genetically modified to express a CD19...
FDA Approval of Siltuximab for Multicentric Castleman’s Disease
INSIDE THE BLACK BOX is an occasional column providing insight into the FDA and its policies and procedures. In this installment, FDA hematologist/oncologist Albert Deisseroth, MD, PhD, discusses the recent approval of siltuximab for patients with multicentric Castleman’s disease who are human...
Many Patients With Colorectal Cancer Fail to Receive Adjuvant Chemotherapy
Data from the National Cancer Data Bank (2010–2011) suggest that 30% of patients with colorectal cancer who are eligible for adjuvant chemotherapy fail to receive it, but their odds increase by 30% when surgery is performed by laparoscopy, rather than laparotomy.1 “In this large national database...
Colorectal Cancer Screening Poised for Change
New screening modalities and the customization of the screening population could soon change the way that screening for colorectal cancer is done. At Digestive Disease Week 2014, the largest gathering of gastrointestinal disease specialists in the world, researchers presented data suggesting that...
Gastric Cancer Detected in a Breath Test
By detecting certain volatile organic compounds in exhaled breath, NanoArtificial Nose technology (NA-NOSE) was able to differentiate patients with gastric cancer from those with benign lesions, with high accuracy, in a poster that earned a merit award at Digestive Disease Week 2014, the largest...
Preoperative Breast MRI: Does Higher Sensitivity Equal Better Outcomes?
Breast magnetic resonance imaging (MRI) is superior to more commonly used imaging modalities in preoperative breast cancer staging and should be a key element in routine workup. But despite its high sensitivity for catching cancers, breast MRI still does not deliver maximum value for the patient....
Expert Point of View: Gregory A. Masters, MD, FASCO
This combination shows good activity in the difficult-to-treat second-line setting of NSCLC,” said Gregory A. Masters, MD, FASCO, about the results of the REVEL study reported at the ASCO Annual Meeting. Dr. Masters, who is Attending Physician at the Helen F. Graham Cancer Center and Research...
Chemotherapy Plus Ramucirumab Provides Survival Advantage Over Chemotherapy Alone in Non–Small Cell Lung Cancer
Ramucirumab (Cyramza) added to docetaxel improved overall survival compared to chemotherapy alone in patients with stage IV non–small cell lung cancer (NSCLC) that has progressed on one prior therapy, according to results of a phase III trial presented at the 50th ASCO Annual Meeting.1 The...
Expert Point of View: Sherene Loi, MD PhD
Sherene Loi, MD PhD, Head of the Translational Breast Cancer Genomics Lab at the Peter McCallum Cancer Centre, Victoria, Australia, commented on the N9831 study presentation and referred to her group’s own work on tumor-infiltrating lymphocytes. These investigators have shown a positive association ...
Immune-Related Genes Predictive of Trastuzumab Benefit
Improved relapse-free survival following treatment with adjuvant trastuzumab (Herceptin) appears to be associated with a heightened state of immunologic function, according to genomic analysis that resulted in a 14-gene profile predictive of outcomes in the landmark NCCTG (Alliance) N9831 trial.1...
Expert Point of View: Sharon H. Giordano, MD, MPH
Formal discussant Sharon H. Giordano, MD, MPH, Professor of Medicine and Chair of Health Services Research at The University of Texas MD Anderson Cancer Center, Houston, emphasized how important it is to preserve fertility in these younger patients with breast cancer. “The main downside is an...
Goserelin With Chemotherapy Prevents Early Menopause, Helps Preserve Fertility in Younger Women With Hormone Receptor–Negative Breast Cancer
The good news for younger women with hormone receptor–negative early breast cancer is that adding goserelin (Zoladex), a luteinizing hormone–releasing hormone (LHRH) agonist, to chemotherapy can prevent sudden menopause, better preserve ovarian function and fertility, and lead to successful...
Expert Point of View: Gregory A. Masters, MD, FASCO
At an ASCO press conference held during the Annual Meeting, moderator Gregory A. Masters, MD, FASCO, who is Attending Physician at the Helen F. Graham Cancer Center and Research Institute, Newark, Delaware, commented on the study presented by Liu et al. “This new combination demonstrates how...
Barbara L. McAneny, MD, to Serve as Chair of the AMA Board of Trustees
Barbara L. McAneny, MD, a practicing oncologist from Albuquerque, New Mexico, has been re-elected to the Board of Trustees of the American Medical Association (AMA) and will assume the position of Board Chair when the trustees gather for their first post-election meeting. Dr. McAneny, who has been...
